Advertisement

Topics

PubMed Journals Articles About "Eisai With Oncology Group Biomedicine Doubles Down Boston" RSS

00:21 EST 23rd February 2019 | BioPortfolio

Eisai With Oncology Group Biomedicine Doubles Down Boston PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Eisai With Oncology Group Biomedicine Doubles Down Boston articles that have been published worldwide.

More Information about "Eisai With Oncology Group Biomedicine Doubles Down Boston" on BioPortfolio

We have published hundreds of Eisai With Oncology Group Biomedicine Doubles Down Boston news stories on BioPortfolio along with dozens of Eisai With Oncology Group Biomedicine Doubles Down Boston Clinical Trials and PubMed Articles about Eisai With Oncology Group Biomedicine Doubles Down Boston for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eisai With Oncology Group Biomedicine Doubles Down Boston Companies in our database. You can also find out about relevant Eisai With Oncology Group Biomedicine Doubles Down Boston Drugs and Medications on this site too.

Showing "Eisai with Oncology Group Biomedicine Doubles Down Boston" PubMed Articles 1–25 of 15,000+

Impact of Closed Facebook Group Participation on Female Hematology/Oncology Physicians.

Meaningful connections are an important aspect of career satisfaction. The Hematology Oncology Women Physician Group (HOWPG) is a private Facebook (FB) group of 936 women who practice within the hematology/oncology (H/O) field. We hypothesized that HOWPG adds value to education, emotional wellness, and practice of oncology for its membership. A survey was conducted within HOWPG to define group impact on members.


New Challenges in Oncology for the Brazilian Private Health Sector: Specialists' Concerns After the ISPOR International Congress in Boston, Massachusetts, 2017.

The congress of the International Society for Pharmacoeconomics and Outcomes Research is one of the main worldwide forums for the dissemination of research and knowledge on healthcare economics. Brazil is the largest country in Latin America, with a per-capita gross domestic product of $15 200 in 2017 and healthcare expenditure of the order of $1 318 per inhabitant. Brazilian specialists participated actively in the society's latest congress, which took place in Boston, Massachusetts, from May 20 to 24, 201...

Boston type I keratoprosthesis implantation technique : Video article.

Keratoprosthetics refer to the replacement of human corneal tissue with an artificially produced exchange product. The most widely implanted keratoprosthesis worldwide is the Boston Type I Keratoprosthesis (BI-KPro, Massachusetts Eye and Ear Infirmary, Boston, MA, USA).


Texas Cardiologist Recalls Boston Marathon Bombing.

When two pressure-cooker bombs filled with nails, ball bearings, and black powder exploded at the finish line of the 2013 Boston Marathon, killing three people and wounding hundreds more, Jorge Alvarez, MD, did what he believes anybody would do: Run toward the danger.

Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.

We conducted a randomized phase III trial to determine whether adjuvant chemotherapy improves survival in women with uterine leiomyosarcoma.

Conformal Radiation Therapy for Pediatric Patients with Low-Grade Glioma: Results from the Children's Oncology Group Phase II Study XXXX.

To determine the rate of marginal relapse, progression-free survival (PFS), and overall survival (OS) in patients with pediatric low-grade glioma (PLGG) treated with conformal radiation therapy (CRT) with a clinical target volume (CTV) margin of 5 mm in the Children's Oncology Group trial XXXX.

Treatment Approach and Outcomes in Infants with Localized Rhabdomyosarcoma: A Report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

For infants with localized rhabdomyosarcoma enrolled on Children's Oncology Group (COG) ARST0331 and ARST0531, local therapy guidelines were provided but adherence was not mandated given toxicity concerns. We examined adherence to protocol local therapy guidelines, treatment variations, and outcomes for these infants.

Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial.

Children with histologically diagnosed high-risk medulloblastoma, supratentorial primitive neuroectodermal tumor of the CNS (CNS-PNET), and pineoblastoma (PBL) have had poor survival despite intensive treatment. We included these patients in this Children's Oncology Group trial. Molecular profiling later revealed tumor heterogeneity that was not detectable at protocol inception. Enrollment of patients with CNS-PNET/PBL was subsequently discontinued, and outcomes for this part of the study are reported here.

Comparative Outcomes of Boston Keratoprosthesis Type 1 Implantation Based on Vision in the Contralateral Eye.

To compare the outcomes of Boston keratoprosthesis type 1 implantation after failed keratoplasty in patients who are blind or sighted in the contralateral eye.

Hematopoietic Stem Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group.

Children and young adults with hypodiploid B-lymphoblastic leukemia (B-ALL) fare poorly and hematopoietic stem cell transplantation (HSCT) is often pursued in first complete remission (CR1). We retrospectively reviewed the outcomes of children and young adults with hypodiploid B-ALL who were enrolled in recent Children's Oncology Group (COG) trials to evaluate the impact of HSCT on outcome.

Outcomes of Patients with 3rd or Higher Relapsed Classical Hodgkin Lymphoma: Results from the German Hodgkin Study Group.

National Radiation Oncology Medical Student Clerkship Trends From 2013-2018.

Over the past six years, the Radiation Oncology Education Collaborative Study Group (ROECSG) implemented and expanded upon a national standardized curriculum for the fourth-year medical student radiation oncology clerkship. This study hypothesized that this would lead to increased use of structured clerkship educational methods on a national level.

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.

Metastatic breast cancer (MBC) is highly prevalent in middle-aged or elderly patients. Eribulin is a nontaxane microtubule inhibitor, approved for the treatment of pretreated MBC. This multicentric study (sponsored by GIOGer, Italian Group for Geriatric Oncology) was designed to assess the efficacy and tolerability of eribulin, according to parameters usually used in geriatric oncology.

Intraocular Light Scatter in Eyes With the Boston Type 1 Keratoprosthesis.

The Boston keratoprosthesis (KPro) is the most commonly used artificial cornea. It has been proven to be successful for severe corneal disease not amenable to keratoplasty. We have observed our patients reporting debilitating glare despite attaining good visual acuities. This motivated us to objectively measure light scatter in eyes with a KPro.

NCTN Assessment on Current Applications of Radiomics in Oncology.

Radiomics is a fast-growing research area based on converting standard-of-care imaging into quantitative minable data and building subsequent predictive models to personalize treatment. It has been proposed as a study objective in clinical trial concepts and a potential biomarker for stratifying patients across interventional treatment arms. In recognizing the growing importance of radiomics in oncology a group of medical physicists and clinicians from NRG Oncology reviewed the current status of the field a...

New intraoperative imaging technologies: Innovating the surgeon's eye toward surgical precision.

Imaging is one of the pillars for the ongoing evolution of surgical oncology toward a precision paradigm. In the present overview, some established or emerging intraoperative imaging technologies are described in light of the vision and experience of our group in image-guided surgery, focusing on digestive surgical oncology.

Boston Type 2 keratoprosthesis- mid term outcomes from a tertiary eye care centre in India.

To analyse the anatomical and functionaloutcomes of Boston type II keratoprosthesis at a tertiary eye care centre in South India. Retrospective chart review of 10 patients operated with Boston keratoprosthesis Type 2 between Feb 2013 and June 2017 were analysed. Outcome measures analysed included, visual outcome, device retention and postoperative complications. The most common indication for surgery was SJS in 80% (8 of 10 eyes). Mean follow-up duration was 2.75 years (0.5-5 years, SD - 1.71, median 32...

Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.

Anthracyclines are part of many effective pediatric cancer treatment protocols. Most pediatric oncology treatment groups assume that the hematologic toxicity of anthracycline agents is equivalent to their cardiotoxicity; for example, Children's Oncology Group substitution rules consider daunorubicin and epirubicin isoequivalent to doxorubicin, whereas mitoxantrone and idarubicin are considered 4 to 5 times as toxic as doxorubicin.

FDG / PET-CT based lymph node atlas in breast cancer patients.

The aim of this study was to localize loco-regional lymph node metastases using positron emission tomography with fluorine 18 fluorodeoxyglucose/computed tomography (FDG-PET/CT) datasets in a large cohort of patients and to evaluate the existing Radiation Therapy Oncology Group (RTOG) clinical target volume (CTV) and the European SocieTy for Radiotherapy & Oncology (ESTRO) CTV contouring guidelines.

Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.

Concurrent chemoradiotherapy (CCRT) is superior to radiotherapy alone for treating locoregionally advanced nasopharyngeal carcinoma (NPC). Whether adding induction chemotherapy (IC) further improves the outcome warrants investigation.

LBA-008Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO).

Outcomes of the Boston Type I Keratoprosthesis as the Primary Penetrating Corneal Procedure.

To report the outcomes of the Boston type I keratoprosthesis (KPro) as the primary penetrating corneal procedure.

Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.

The knowledge in the field of castration-resistant prostate cancer (CRPC) is developing rapidly, with emerging new therapies and advances in imaging. Nonetheless, in multiple areas there is still a lack of or very limited evidence, and clear guidance from clinicians regarding optimal strategy is required.

Testis Involvement in Neuroblastoma: Report of 3 Cases in the Turkish Pediatric Oncology Group-Neuroblastoma Study and Review of the Literature.

Neuroblastoma (NB) is the most common extracranial solid tumor of childhood. Primary and secondary testicular involvement is extremely uncommon in neuroblastoma.

Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.

Oncogenic BRAF and RAS mutations as well as multiple known (and yet unknown) RET fusion oncogenes comprise the majority of causative molecular alterations in papillary thyroid carcinoma (PTC). Apparently "mutation-negative" PTCs encompass a heterogenous group impeding analysis of prognostic significance of underlying genetics.


Advertisement
Quick Search
Advertisement
Advertisement